University of Texas PDX Development and Trial Center Grant

The goal for the University Texas PDX Development and Trial Center (UTPDTC) is to optimize personalized biomarker-based cancer therapy and identify effective targeted drugs based on the molecular characteristics of each tumor. Our short-term goals are to establish a biobank of clinically, and molecularly-annotated Patient-Derived Xenografts (PDXs) and to use PDXs as a platform for preclinical drug development and biomarker discovery. The primary goal for UTPDTC investigators will be to develop PDX trial strategies for preclinical testing of single agents and drug combinations. These models will allow the determination of the optimal treatments (single drugs or combinations) that should be tested in clinical trials in increasingly individualized, molecularly defined subsets of tumors. The goal of the Patient-Derived Xenograft Core is to provide high-quality clinically relevant and molecularly annotated PDX models for the research projects proposed in the University of Texas PDX Development and Trial Center (UTPDTC) grant application and to the research activity of the NCI PDX Development and Trial Centers Research Network (PDXNet) by leveraging PDX resources at our institutions and developing new PDX models from human cancer specimens using rigorous quality standards so that the models can be used to guide clinical trial development. The PDX models developed and/or characterized by the PDX Core will be available to other cancer researchers through the PDXNet and NCI Patient-Derived Models Repository (PDMR).

• Study Design:
  • Prospective Longitudinal Cohort
• Study Type:
  • Cohort
• Total number of consented subjects: 36
• Subject Sample Telemetry Report (SSTR)

• BioProject
• Sequence Read Archive
• BioSample
• MeSH
• Gene

Inclusion Criteria:

1. Age ≥ 18 years
2. Must provide an informed consent
3. Non-smokers, current smokers, and former smokers who are scheduled for bronchoscopy, biopsy, and pleural fluid drainage procedures
4. Non-smokers, current smokers, and former smokers who are scheduled for surgical resection of lung cancer
5. Confirmed diagnosis of lung cancer
6. Suspected diagnosis of lung cancer

Exclusion Criteria:

1. Patients at risk of bleeding such as known bleeding disorder and abnormal coagulation studies on screening
2. Inability to provide an informed consent
3. Contradictions to fiberoptic bronchoscopy including hemodynamic instability and severe obstructive airway disease (as determined by spirometry)

• Primary Phenotype: Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Small Cell Lung Carcinoma

• EGFR
• KRAS
• STK11
• TP53

• Principal Investigator
  • Jack A Roth, MD. MD Anderson Cancer Center, Houston, TX, USA.
• Funding Source
  • U54CA224065. National Institutes of Health, Bethesda, MD, USA.